Last month the Duchenne Research Fund participated in the UK National Workshop on Duchenne Muscular Dystrophy Clinical Trial Capacity at Newcastle University, hosted by TREAT-NMD. The landmark meeting brought together 75 representatives from patient organisations, pharmaceutical companies, the National Institute for Health Research and a wide range of clinicians, to discuss the challenges and solutions to increase clinical trial capacity in the UK.
As a result of the meeting, TREAT-NMD has published the Newcastle Plan, which outlines three stages of development over the next five years, intended to cement the UK as a centre for clinical trials for Duchenne muscular dystrophy and ensure all patients with Duchenne – both children and adults – have access to clinical research opportunities.
The Duchenne Research Fund will remain closely involved in the Plan as part of a patient organisation group that will help co-ordinate the process and identify funding options. The next meeting is in September.
To read the full summary document published by TREAT-NMD, please click here.
